Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although ICIs have proven highly effective for adult cancers, initial phase I/II clinical trials using single-agent ICIs against unselected pediatric cancers have been overall disappointing. With the exception of pediatric classic Hodgkin lymphoma, responses to ICIs have been infrequent, likely stemming from an inherent difference in the immunogenicity of childhood cancers, which, on average, have far fewer neoantigens than adult cancers. Recently, however, hope has reemerged that certain subsets of children with cancer may benefit from ICI therapies. In preliminary studies, patients with both pediatric hypermutated and SMARCB1-deficient cancers have had impressive responses to ICI therapies, likely as a result of underlying biologies that enhance neoantigen expression and tumoral inflammation. Dedicated trials are ongoing to fully evaluate the efficacy of ICIs for patients with these subsets of pediatric cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Across four prior studies evaluating ICI monotherapy regimens in children with solid tumors and lymphoma, the collective ORR was 3.7% for the solid tumor population (nine responses in 244 patients) (17).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [17]
In the citing paper
“Unfortunately, to date, no objective responses have been reported with any ICI combination regimen in young children (age <10 years) with a solid tumor (8, 17).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [17]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 989
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Comprehensive Analysis of Hypermutation in Human Cancer
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., Davidson, S., Edwards, M., Elvin, J. A., Hodel, K. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.048 · Cited by 765
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0327 · Cited by 578
Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D. T. W., Sturm, D., Hermann, C., Segura Wang, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.001 · Cited by 571
Noncoding regions are the main source of targetable tumor-specific antigens
Laumont, C. M., Vincent, K., Hesnard, L., Audemard, É., Bonneil, É., Laverdure, J.-P., Gendron, P., Courcelles, M., Hardy, M.-P., Côté, C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5516 · Cited by 535
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0131-9 · Cited by 454
Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J., López-Picazo, J. M., Machiels, J.-P., Delord, J.-P., Evans, T. R. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00739 · Cited by 440
INI1-Deficient Tumors: Diagnostic Features and Molecular Genetics
Hollmann, T. J., & Hornick, J. L. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822b325b · Cited by 427
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R. R., Cochran, A. J., Comin-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 376
for the Biallelic Mismatch Repair Deficiency Consortium, Shlien, A., Campbell, B. B., de Borja, R., Alexandrov, L. B., Merico, D., Wedge, D., Van Loo, P., Tarpey, P. S., Coupland, P., et al. (2015) · Nature Genetics · doi:10.1038/ng.3202 · Cited by 374
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Davis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Self-citationPhase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
Subbiah, V., Solit, D. B., Chan, T. A., & Kurzrock, R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.002 · Cited by 252
Tabori, U., Hansford, J. R., Achatz, M. I., Kratz, C. P., Plon, S. E., Frebourg, T., & Brugières, L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0574 · Cited by 227
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Rousseau, B., Foote, M. B., Maron, S. B., Diplas, B. H., Lu, S., Argilés, G., Cercek, A., & Diaz, L. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2031965 · Cited by 211
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30693-x · Cited by 171
Self-citationClonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Leruste, A., Tosello, J., Ramos, R. N., Tauziède-Espariat, A., Brohard, S., Han, Z.-Y., Beccaria, K., Andrianteranagna, M., Caudana, P., Nikolic, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 161
Self-citationHuang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Chun, H.-J. E., Lim, E. L., Heravi‐Moussavi, A., Saberi, S., Mungall, K., Bilenky, M., Carles, A., Tse, K., Shlafman, I., Zhu, K., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.009 · Cited by 157
Msaouel, P., Malouf, G. G., Su, X., Yao, H., Tripathi, D. N., Soeung, M., Gao, J., Rao, P., Coarfa, C., Creighton, C. J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2020.04.002 · Cited by 156
Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01581-6 · Cited by 155
Self-citationGalvano, A., Gristina, V., Malapelle, U., Pisapia, P., Pepe, F., Barraco, N., Castiglia, M., Perez, A., Rolfo, C. D., Troncone, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100124 · Cited by 144
Role of POLE and POLD1 in familial cancer
Mur, P., García-Mulero, S., del Valle, J., Magraner-Pardo, L., Vidal, A., Pineda, M., Cinnirella, G., Martín-Ramos, E., Pons, T., López-Doriga, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0922-2 · Cited by 140
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 124
Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome
Durno, C. A., Sherman, P. M., Aronson, M. D., Malkin, D. M., Hawkins, C. E., Bakry, D., Bouffet, É., Gallinger, S., Pollett, A. F., Campbell, B. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.008 · Cited by 111
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
Geoerger, B., Bergeron, C., Gore, L., Sender, L., Dunkel, I. J., Herzog, C., Brochez, L., Cruz, O., Nysom, K., Berghorn, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.032 · Cited by 98
Bigot, J., Lalanne, A. I., Lucibello, F., Gueguen, P., Houy, A., Dayot, S., Ganier, O., Gilet, J., Tosello, J., Nemati, F., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0555 · Cited by 95
Li, Y., Ma, Y., Wu, Z., Zeng, F., Song, B., Zhang, Y., Li, J., Lui, S., & Wu, M. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751407 · Cited by 95
Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangadhar, T. C., Hersey, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3005 · Cited by 89
Beckermann, K. E., Jolly, P. C., Kim, J. Y., Bordeaux, J., Puzanov, I. J., Rathmell, W. K., & Johnson, D. B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0206-1 · Cited by 87
Chung, J., Maruvka, Y. E., Sudhaman, S., Kelly, J., Haradhvala, N. J., Bianchi, V., Edwards, M., Forster, V. J., Nunes, N. M., Galati, M. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0790 · Cited by 87
Self-citationDurno, C. A., Boland, C. R., Cohen, S., Dominitz, J. A., Giardiello, F. M., Johnson, D. A., Kaltenbach, T. R., Levin, T. R., Lieberman, D. A., Robertson, D. J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.011 · Cited by 66
Zraly, C. B., & Dingwall, A. K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks288 · Cited by 50
Alternative Splicing in Tumors — A Path to Immunogenicity?
Slansky, J. E., & Spellman, P. T. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1814237 · Cited by 48
Williamson, L. M., Rive, C. M., Francesco, D. D., Titmuss, E., Chun, H.-J. E., Brown, S. D., Milne, K., Pleasance, E., Lee, A. F., Yip, S. S. F., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00238-4 · Cited by 39
Davis, K. L., Fox, E., Reid, J. M., Liu, X., Minard, C. G., Weigel, B., & Mackall, C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.10526 · Cited by 37
Self-citationPecora, A. L., Halpern, S. L., Weber, M. S., Paleoudis, E. G., Panush, D., Patterson, F. R., & Toretsky, J. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000332 · Cited by 33
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
Sodji, Q. H., Klein, K., Kavuri, S., & Parikh, J. R. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0267-9 · Cited by 32
Lynch Syndrome: A Pediatric Perspective
Huang, S. C., Durno, C. A., & Erdman, S. H. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000179 · Cited by 22
Stefano, R. F. D., Buttigliero, C., Luca, E. D., Reale, M. L., Pisano, C., Leone, G., Zichi, C., Massa, F., Manfredi, M., Vignani, F., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.011 · Cited by 5
Research works printed but not linked: 3
- Loeb DM, Cancer Immunol Immunother.
- Morgenstern DA, 2021, J Clin Orthod., 39, 15
- Chung HC, 2018, J Clin Oncol., 36, 15
Cited by
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 74
“The failure of ICI in unselected pediatric cancers has led to recommendations of avoiding ICI monotherapy trials in children without robust biological rationale (19, 20).”
BackgroundSelf-citationImmune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma
Padilla, O. A., Minns, H. E., Wei, H.-J., Fan, W., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Gallitto, M., Yeh, R., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.219 · Cited by 42
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Ciurej, A., Lewis, E. C., Gupte, A., & Al‐Antary, E. T. (2023) · Vaccines · doi:10.3390/vaccines11121843 · Cited by 24
“Due, in part, to the low incidence of pediatric melanoma and resulting low sample size in related clinical trials, the FDA used extrapolation with adult patient data to approve ipilimumab for unresectable or metastatic melanoma in pediatric patients older than 12 years in 2017 [45].”
BackgroundMethodInfluentialMünter, D., de Faria, F. W., Richter, M., Aranda-Pardos, I., Hotfilder, M., Walter, C., Paga, E., Inserte, C., Albert, T., Roy, R., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.031 · Cited by 23
Metadata
- Authors
- Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L.
- Affiliations
- Stanford Medicine (US)
- University of Toronto (CA)
- Université Paris Sciences et Lettres (FR)
- Institut Curie (FR)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 781-794
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280529326
- Cited by
- 53
- References
- 90
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 18 · 2023: 8 · 2022: 3
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- immune checkpoint inhibitors, childhood cancer, pediatric Hodgkin lymphoma, neoantigens, tumor immunogenicity, antitumor T-cell responses, immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Child, Hodgkin Disease, Humans, Immunologic Factors, Immunotherapy, Pediatrics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.